NHS declines to approve Alzheimer’s drug donanemab over cost and effectiveness concerns
Summary: The UK’s National Institute for Health and Care Excellence (Nice) has declined to approve the Alzheimer’s drug donanemab for NHS use, despite its approval by the Medicines and Healthcare Regulatory Authority. Nice cited concerns over cost-effectiveness and modest benefits.
Donanemab, which targets amyloid plaques in the brain, is not a cure and shows limited improvement in symptoms. Clinical trials indicated only a small difference in cognitive decline compared to a placebo, raising questions about its overall effectiveness.
Additionally, donanemab has significant side effects, including brain swelling and bleeding. Nice emphasized the need for careful consideration of treatment options, prioritizing social care and support for families affected by Alzheimer’s.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings